B
Bull
Bull · 25%SHC
$12.30
Precio del escenario
$19.030
+0.070 (+0.37%)Al cierre
Loading chart…
- High
- 19.210
- Open
- 19.190
- VWAP
- 18.95
- Vol
- 2.47M
- Mkt Cap
- 3.37B
- Low
- 18.600
- Amount
- 46.80M
- EV/EBITDA, TTM
- 11.56
Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company's segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Its Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.
AI analysis of Sotera Health Co (SHC)
buySotera Health Co (SHC) is a good buy right now, trading at $19.27 with a forward P/E of 19.72, indicating potential for growth. The company reported Q2 revenue of $321.4 million, exceeding expectations, and has a gross margin of 54.44%, demonstrating strong profitability. The main risk is its organic revenue growth, which has averaged only 4.9% year-on-year, suggesting challenges in demand.
Métricas de valoración
The current forward P/E ratio for Sotera Health Co (SHC) is 19.68, compared to its 5-year average forward P/E of 18.22.
Alphio AI Price Scenarios for SHC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SHC
Cronología de eventos
Noticias
9.508-16Yahoo FinanceSotera Health Q2 Earnings Analysis: Buy, Sell, or Hold?
2.008-13NASDAQ.COMSotera Health (SHC) Q2 2026 Earnings Call Transcript
9.508-10Yahoo FinanceSotera Health Q2 Results Exceed Expectations
9.508-06seekingalphaSotera Health Q2 2026 Earnings Highlights
9.507-29Yahoo FinanceShaftesbury Capital Reports Strong H1 Growth Across Key Metrics
SHC FAQ — answered by Alphio AI
Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company's segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Its Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).
Sotera Health Co (SHC) is a good buy right now, trading at $19.27 with a forward P/E of 19.72, indicating potential for growth. The company reported Q2 revenue of $321.4 million, exceeding expectations, and has a gross margin of 54.44%, demonstrating strong profitability. The main risk is its organic revenue growth, which has averaged only 4.9% year-on-year, suggesting challenges in demand.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.